[Therapeutic bacterial vaccine Immunovac in complex treatment of patients with chronic pyoderma].
OBJECTIVE
Assessment of therapeutic effect and immunologic parameters during use of Immunovac vaccine for complex treatment of chronic forms of pyoderma.


METHODS
Ninety-five patients with different clinical forms of chronic pyoderma (furunculosis, hydradenitis, chronic ulcerative and ulcerative-vegetans pyoderma, folliculitis, impetigo etc.) were studied. Fifty-nine patients received immunotherapy with Immunovac vaccine together with basic therapy and 36 patients comprised control group treated only with basic therapy. Studied immunologic parameters were as follows: assessment of functional activity of lymphocytes, determination of lymphocyte subpopulations by flow cytometry, total immunoglobulins classes A, G, M by radial immunoduffusion, affinity of antibodies by enzyme immunoassay, levels of IFNalpha and IFNgamma.


RESULTS
Use of Immunovac vaccine in complex treatment of patients with chronic forms of pyoderma enhanced clinical effect of basic therapy, which expressed in decrease of severity and frequency of disease relapses irrespective to clinical form and severity of pyoderma. Therapeutic effect during use of Immunovac vaccine amounted 84.7%, whereas in control group it was 41.6% after 12 months of follow-up. Increase of functional activity of neutrophils, subpopulation of lymphocytes with markers CD4+, CD8+, CD72+, affinity of antibodies as well as induced production of IFNalpha and IFNgamma was revealed. Correction of immunologic parameters correlated with positive results of patients treatment.


CONCLUSIONS
Inclusion of bacterial polycomponent vaccine Immunovac in complex treatment of patients with chronic pyoderma promotes enhancement of therapeutic effect of basic therapy and correction of immunologic parameters.
Sorokina
E V
EV
Masiukova
S A
SA
Kurbatova
E A
EA
Egorova
N B
NB
D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis; D000944:Antigens, Differentiation, B-Lymphocyte / Q000096:biosynthesis; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D015704:CD4 Antigens / Q000096:biosynthesis; D016827:CD8 Antigens / Q000096:biosynthesis; D002908:Chronic Disease; D006801:Humans; D007136:Immunoglobulins / Q000097:blood / Q000276:immunology; D007167:Immunotherapy; D016898:Interferon-alpha / Q000097:blood; D007371:Interferon-gamma / Q000097:blood; D018655:Lymphocyte Count; D008875:Middle Aged; D011711:Pyoderma / Q000097:blood / Q000276:immunology / Q000628:therapy*; D055502:Secondary Prevention; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome; D017778:Vaccines, Combined / Q000627:therapeutic use
D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D001428:Bacterial Vaccines; D015704:CD4 Antigens; C064228:CD72 protein, human; D016827:CD8 Antigens; D007136:Immunoglobulins; D016898:Interferon-alpha; D017778:Vaccines, Combined; D007371:Interferon-gamma